Dr. Vincent K. Lam, MD

Dr. Lam practices at Johns Hopkins Bayview Medical Center in Baltimore, Maryland, part of Johns Hopkins Health System.

Dr. Lam's NPI, 1265758601, was assigned on April 9, 2010. Dr. Lam graduated from University of California, San Francisco School of Medicine in 2010. Dr. Lam holds Maryland license D75865.

Dr. Lam's primary practice is Johns Hopkins Bayview Medical Center, at 4940 Eastern Avenue, Baltimore, MD 21224 in Baltimore City. The practice phone is (410) 550-0123.

Dr. Lam's primary practice is Johns Hopkins Bayview Medical Center in Baltimore, Maryland, part of Johns Hopkins Health System. Dr. Lam is also affiliated with The Johns Hopkins Hospital. The medical group on file is Johns Hopkins University. Dmand AI also links Dr. Lam to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lam practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Lam's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Lam's licenses on file in 2 states: Maryland and Texas.

CMS data shows 373 Medicare services from Dr. Lam across 3 procedure codes in 2024, for 135 Medicare patients. Medicare paid $44,620 for them.

CMS counts 135 Medicare patients who saw Dr. Lam in 2024. The largest group is 65 to 74, with 72 patients. 75% of them have cancer, and 73% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.61, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lam's median patient age at 70, with 53% women.

In 2024, Dr. Lam wrote 162 Medicare Part D claims for 46 patients. 59% of them were for generic drugs. CMS names the drug for 109 of them, across 6 drugs with 11 or more claims each, at $844,409 in total drug cost. In 2023, CMS named 32 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Lam for performance year 2024, reported as part of a group. CMS lists Dr. Lam as offering telehealth.

Dmand AI links 59 papers to Dr. Lam, published from 2014 to 2025. 2024 was the busiest year, with 10. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Biomarkers, Tumor. Dr. Lam has published most often in J Thorac Oncol. Dr. Lam's most frequent co-authors are Josephine Feliciano, MD, Patrick Forde, MD and Christine Lee Hann, MD, PhD.

Dmand AI links Dr. Lam to 8 clinical trials, 4 of them phase 1 studies. 4 are still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Carcinoma, Transitional Cell. Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins sponsors the most, 2.

CMS Open Payments shows 122 general payments to Dr. Lam from 20 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 70% of the total. Bristol-Myers Squibb Company paid the most, $28,364. It also lists 8 research payments totaling $959 in 2018.

Dr. Lam graduated from University of California, San Francisco School of Medicine in 2010.